Research programme: HIV maturation inhibitors - Myriad Pharmaceuticals
Alternative Names: HIV maturation inhibitors - Myriad Pharmaceuticals; MPI-0461359; MPI-461359Latest Information Update: 26 Nov 2012
Price :
$50 *
At a glance
- Originator Myriad Pharmaceuticals
- Developer Myrexis
- Class Small molecules
- Mechanism of Action Nucleocapsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections